Mesothelioma

The Onconase franchise includes the gateway indication of malignant The Bloomfield, New Jersey-based company said Onconase is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease technology.

A natural protein isolated from the leopard frog, Onconase has been shown to target cancer cells while sparing normal cells.

Onconase triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

ACEL is trading at $2.87, up $0.38 or 15.26% on a volume of 2.16 million shares.

Copyright(c) 2007 RealTimeTraders.com, Inc.

All Rights Reserved Related Articles Alfacell, Onconase Inhibits Tumor Growth Of Non-small Cell Lung Cancer, Breast Cancer Cells - Update Alfacell Corp.

Is Trading Higher In Pre-open Following News Alfacell Says Preclinical Data Show ONCONASE Inhibits Tumor Growth Of Non-Small Cell Lung Cancer, Breast Cancer Cells - Quick Facts *Alfacell Says Preclinical Data Show ONCONASE Inhibits Tumor Growth Of Non-Small Cell Lung Cancer, Breast Cancer Cells Alfacell Says Vivo Study R...

Read more...